Metyrapone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01011 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 42 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | exercise-induced malignant hyperthermia | KG + DL |
| 2 | malignant hyperthermia, susceptibility to | KG + DL |
| 3 | King-Denborough syndrome | KG + DL |
| 4 | central core myopathy | KG + DL |
| 5 | moderate multiminicore disease with hand involvement | KG + DL |
| 6 | congenital multicore myopathy with external ophthalmoplegia | KG + DL |
| 7 | myopathy, centronuclear | KG + DL |
| 8 | familial periodic paralysis | KG + DL |
| 9 | renal tubular acidosis | KG + DL |
| 10 | malignant hyperthermia of anesthesia | KG + DL |
| 11 | hypokalemic periodic paralysis | KG + DL |
| 12 | thyrotoxic periodic paralysis | KG + DL |
| 13 | thyrotoxic periodic paralysis, susceptibility to | KG + DL |
| 14 | X-linked centronuclear myopathy | KG + DL |
| 15 | myopathy, tubular aggregate | KG + DL |
| 16 | periodic paralysis (disease) | KG + DL |
| 17 | seborrheic keratosis | KG + DL |
| 18 | vulvar inverted follicular keratosis | KG + DL |
| 19 | motor nerve neuritis | KG + DL |
| 20 | fetal erythroblastosis | KG + DL |
| 21 | retinal disease | KG + DL |
| 22 | obsolete hyperuricemia (disease) | KG + DL |
| 23 | pituitary apoplexy | KG + DL |
| 24 | dyspepsia | KG + DL |
| 25 | vestibular neuronitis | KG + DL |
| 26 | cleidocranial dysplasia | KG + DL |
| 27 | brachial plexus neuritis | KG + DL |
| 28 | neuroendocrine disease | KG + DL |
| 29 | neuroretinitis | KG + DL |
| 30 | acne (disease) | KG + DL |
| 31 | myopathic intestinal pseudoobstruction | KG + DL |
| 32 | unclassified intestinal pseudoobstruction | KG + DL |
| 33 | paraneoplastic neurologic syndrome | KG + DL |
| 34 | intestinal obstruction | KG + DL |
| 35 | familial visceral myopathy | KG + DL |
| 36 | lethal multiple pterygium syndrome | KG + DL |
| 37 | nasal cavity disease | KG + DL |
| 38 | optic papillitis | KG + DL |
| 39 | hypouricemia, renal | KG + DL |
| 40 | microcephaly microphthalmos blindness | KG + DL |
| 41 | neuronal intestinal dysplasia, type B | KG + DL |
| 42 | hypoxanthine guanine phosphoribosyltransferase partial deficiency | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.